Prevention therapy and prognosis/monitoring in sepsis and septic shock
AssigneeNederlandse Organisatie voor toegepastnatuurwetenschappelijk Onderzoek TNO
InventorsPatrick Cornelis Nicolaas Rensen, Aloysius Maria Havekes
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a peptide which binds to lipopolysaccharide (LPS) or lipoteichoic acid (LTA), for manufacturing a pharmaceutical composition for treating sepsis or septic shock, wherein the peptide comprises the amino acid sequence of apolipoprotein CI (apoCI) or a part thereof that comprises at least the amino acids of the C-terminal helix of apoCI. The use of human apoCI is preferred. The peptide can be administered clinically to patients who have sepsis or threaten to develop sepsis. Measurement of the apoCI content in blood can be utilized for determining the severity and prognosis of the course of the septic condition or for monitoring an anti-sepsis treatment.
Claims15
A method for treating a mammal suffering from or at risk of developing sepsis or septic shock comprising administering to such mammal a therapeutically effective amount therefor of a peptide and pharmaceutically acceptably adjuvants, wherein the peptide has an amino acid sequence comprising:
- (A) SEQ ID NO.:2 or (B) a fragment of SEQ ID NO.:2 that comprises SEQ ID NO.:11.
Dependencies are inferred from the claim text.